Drug-induced mast cell eradication: a novel approach to treat mast cell activation disorders?

Mast cell (MC) activation is a key event in allergic reactions, other inflammatory states, and MC activation syndromes. MC-stabilizing agents, mediator-targeting drugs, and drugs interfering with mediator effects are often prescribed for these patients. However, the clinical efficacy of these drugs...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Valent, Peter (VerfasserIn) , Akin, Cem (VerfasserIn) , Hartmann, Karin (VerfasserIn) , Reiter, Andreas (VerfasserIn) , Gotlib, Jason (VerfasserIn) , Sotlar, Karl (VerfasserIn) , Sperr, Wolfgang R. (VerfasserIn) , Degenfeld-Schonburg, Lina (VerfasserIn) , Smiljkovic, Dubravka (VerfasserIn) , Triggiani, Massimo (VerfasserIn) , Horny, Hans-Peter (VerfasserIn) , Arock, Michel (VerfasserIn) , Galli, Stephen J. (VerfasserIn) , Metcalfe, Dean D. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: June 2022
In: The journal of allergy and clinical immunology
Year: 2022, Jahrgang: 149, Heft: 6, Pages: 1866-1874
ISSN:1097-6825
DOI:10.1016/j.jaci.2022.04.003
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jaci.2022.04.003
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0091674922004511
Volltext
Verfasserangaben:Peter Valent, Cem Akin, Karin Hartmann, Andreas Reiter, Jason Gotlib, Karl Sotlar, Wolfgang R. Sperr, Lina Degenfeld-Schonburg, Dubravka Smiljkovic, Massimo Triggiani, Hans-Peter Horny, Michel Arock, Stephen J. Galli, and Dean D. Metcalfe

MARC

LEADER 00000caa a2200000 c 4500
001 1880516861
003 DE-627
005 20240307075825.0
007 cr uuu---uuuuu
008 240212s2022 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.jaci.2022.04.003  |2 doi 
035 |a (DE-627)1880516861 
035 |a (DE-599)KXP1880516861 
035 |a (OCoLC)1425215484 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Valent, Peter  |d 1962-  |e VerfasserIn  |0 (DE-588)1112048979  |0 (DE-627)866035079  |0 (DE-576)47634705X  |4 aut 
245 1 0 |a Drug-induced mast cell eradication: a novel approach to treat mast cell activation disorders?  |c Peter Valent, Cem Akin, Karin Hartmann, Andreas Reiter, Jason Gotlib, Karl Sotlar, Wolfgang R. Sperr, Lina Degenfeld-Schonburg, Dubravka Smiljkovic, Massimo Triggiani, Hans-Peter Horny, Michel Arock, Stephen J. Galli, and Dean D. Metcalfe 
246 3 3 |a Drug-induced mast cell eradication: a novel approach to treat mast cell activation disorders 
264 1 |c June 2022 
300 |a 9 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Online verfügbar: 12. April 2022, Artikelversion: 3. Juni 2022 
500 |a Gesehen am 12.02.2024 
520 |a Mast cell (MC) activation is a key event in allergic reactions, other inflammatory states, and MC activation syndromes. MC-stabilizing agents, mediator-targeting drugs, and drugs interfering with mediator effects are often prescribed for these patients. However, the clinical efficacy of these drugs varies depending on the numbers of involved MCs and the underlying pathology. One straightforward approach would be to eradicate the primary target cell. To date however, no MC-eradicating treatment approach has been developed for patients with MC activation disorders. Nevertheless, recent data suggest that long-term treatment with agents effectively inhibiting KIT function results in the virtual eradication of tissue MCs and a sustained decrease in serum tryptase levels. In many of these patients, MC depletion is associated with a substantial improvement in mediator-induced symptoms. In patients with an underlying KIT D816V-positive mastocytosis, such MC eradication requires an effective inhibitor of KIT D816V, such as avapritinib. However, the use of KIT inhibitors must be balanced against their potential side effects. Here we discuss MC-eradicating strategies in various disease models, the feasibility of this approach, available clinical data, and future prospects for the use of KIT-targeting drugs in MC activation disorders. 
650 4 |a avapritinib 
650 4 |a KIT 
650 4 |a Mast cell activation syndrome 
650 4 |a Mast cells 
650 4 |a midostaurin 
650 4 |a tyrosine kinase inhibitor 
700 1 |a Akin, Cem  |e VerfasserIn  |4 aut 
700 1 |a Hartmann, Karin  |e VerfasserIn  |4 aut 
700 1 |a Reiter, Andreas  |d 1964-  |e VerfasserIn  |0 (DE-588)172629551  |0 (DE-627)697563766  |0 (DE-576)133488594  |4 aut 
700 1 |a Gotlib, Jason  |e VerfasserIn  |4 aut 
700 1 |a Sotlar, Karl  |e VerfasserIn  |4 aut 
700 1 |a Sperr, Wolfgang R.  |e VerfasserIn  |4 aut 
700 1 |a Degenfeld-Schonburg, Lina  |e VerfasserIn  |0 (DE-588)1317525116  |0 (DE-627)1879420023  |4 aut 
700 1 |a Smiljkovic, Dubravka  |e VerfasserIn  |4 aut 
700 1 |a Triggiani, Massimo  |e VerfasserIn  |4 aut 
700 1 |a Horny, Hans-Peter  |e VerfasserIn  |4 aut 
700 1 |a Arock, Michel  |e VerfasserIn  |4 aut 
700 1 |a Galli, Stephen J.  |e VerfasserIn  |4 aut 
700 1 |a Metcalfe, Dean D.  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t The journal of allergy and clinical immunology  |d Amsterdam [u.a.] : Elsevier, 1971  |g 149(2022), 6 vom: Juni, Seite 1866-1874  |h Online-Ressource  |w (DE-627)32045553X  |w (DE-600)2006613-2  |w (DE-576)094478864  |x 1097-6825  |7 nnas  |a Drug-induced mast cell eradication: a novel approach to treat mast cell activation disorders? 
773 1 8 |g volume:149  |g year:2022  |g number:6  |g month:06  |g pages:1866-1874  |g extent:9  |a Drug-induced mast cell eradication: a novel approach to treat mast cell activation disorders? 
856 4 0 |u https://doi.org/10.1016/j.jaci.2022.04.003  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.sciencedirect.com/science/article/pii/S0091674922004511  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20240212 
993 |a Article 
994 |a 2022 
998 |g 172629551  |a Reiter, Andreas  |m 172629551:Reiter, Andreas  |d 60000  |d 61200  |e 60000PR172629551  |e 61200PR172629551  |k 0/60000/  |k 1/60000/61200/  |p 4 
999 |a KXP-PPN1880516861  |e 4483095838 
BIB |a Y 
SER |a journal 
JSO |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"titleAlt":[{"title":"Drug-induced mast cell eradication: a novel approach to treat mast cell activation disorders"}],"person":[{"display":"Valent, Peter","family":"Valent","role":"aut","given":"Peter"},{"given":"Cem","role":"aut","display":"Akin, Cem","family":"Akin"},{"role":"aut","display":"Hartmann, Karin","family":"Hartmann","given":"Karin"},{"display":"Reiter, Andreas","family":"Reiter","role":"aut","given":"Andreas"},{"given":"Jason","role":"aut","display":"Gotlib, Jason","family":"Gotlib"},{"given":"Karl","display":"Sotlar, Karl","family":"Sotlar","role":"aut"},{"given":"Wolfgang R.","family":"Sperr","display":"Sperr, Wolfgang R.","role":"aut"},{"given":"Lina","role":"aut","display":"Degenfeld-Schonburg, Lina","family":"Degenfeld-Schonburg"},{"family":"Smiljkovic","display":"Smiljkovic, Dubravka","role":"aut","given":"Dubravka"},{"given":"Massimo","family":"Triggiani","display":"Triggiani, Massimo","role":"aut"},{"given":"Hans-Peter","role":"aut","family":"Horny","display":"Horny, Hans-Peter"},{"family":"Arock","display":"Arock, Michel","role":"aut","given":"Michel"},{"given":"Stephen J.","family":"Galli","display":"Galli, Stephen J.","role":"aut"},{"family":"Metcalfe","display":"Metcalfe, Dean D.","role":"aut","given":"Dean D."}],"recId":"1880516861","relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"title":[{"title":"The journal of allergy and clinical immunology","subtitle":"official publication of the American Academy of Allergy, Asthma and Immunology","title_sort":"journal of allergy and clinical immunology"}],"note":["Gesehen am 23.08.2021"],"origin":[{"dateIssuedKey":"1971","publisherPlace":"Amsterdam [u.a.] ; St. Louis, Mo.","dateIssuedDisp":"1971-","publisher":"Elsevier ; Mosby"}],"id":{"issn":["1097-6825"],"eki":["32045553X"],"zdb":["2006613-2"]},"pubHistory":["47.1971 -"],"disp":"Drug-induced mast cell eradication: a novel approach to treat mast cell activation disorders?The journal of allergy and clinical immunology","part":{"year":"2022","extent":"9","issue":"6","text":"149(2022), 6 vom: Juni, Seite 1866-1874","pages":"1866-1874","volume":"149"},"recId":"32045553X","type":{"bibl":"periodical","media":"Online-Ressource"}}],"id":{"eki":["1880516861"],"doi":["10.1016/j.jaci.2022.04.003"]},"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"June 2022"}],"language":["eng"],"title":[{"title":"Drug-induced mast cell eradication: a novel approach to treat mast cell activation disorders?","title_sort":"Drug-induced mast cell eradication: a novel approach to treat mast cell activation disorders?"}],"physDesc":[{"extent":"9 S."}],"name":{"displayForm":["Peter Valent, Cem Akin, Karin Hartmann, Andreas Reiter, Jason Gotlib, Karl Sotlar, Wolfgang R. Sperr, Lina Degenfeld-Schonburg, Dubravka Smiljkovic, Massimo Triggiani, Hans-Peter Horny, Michel Arock, Stephen J. Galli, and Dean D. Metcalfe"]},"note":["Online verfügbar: 12. April 2022, Artikelversion: 3. Juni 2022","Gesehen am 12.02.2024"]} 
SRT |a VALENTPETEDRUGINDUCE2022